Jain Global’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Jain Global’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-72,261	Closed	-$83.8K	–	1572
2025 Q2	$83.8K	Buy	+72,261	New	+$95.3K	﹤0.01%	1054

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jain Global's ZNTL Position: Q3 2025 in Review

Jain Global sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 72,261 shares — an estimated $83.8K sold.

Jain Global first reported a position in ZNTL in Q2 2025 and held it in 1 quarter. The position peaked at $83.8K in Q2 2025. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

Jain Global reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Jain Global sold 72,261 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $83.8K.
Jain Global first reported a position in Zentalis Pharmaceuticals in Q2 2025 and held it in 1 quarter.
Jain Global's Zentalis Pharmaceuticals position peaked at $83.8K in Q2 2025.
99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on Jain Global's 13F filing for Q3 2025, filed 14 Nov 2025.